Last reviewed · How we verify
Imidazolyl ethanamide pentandioic acid
Imidazolyl ethanamide pentandioic acid is a small-molecule compound that likely acts as a metabolic modulator or cellular signaling agent, though its precise mechanism remains proprietary.
At a glance
| Generic name | Imidazolyl ethanamide pentandioic acid |
|---|---|
| Also known as | Ingavirin |
| Sponsor | Valenta Pharm JSC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The imidazole moiety and pentandioic acid (glutaric acid) backbone suggest potential involvement in amino acid metabolism, cellular energy pathways, or receptor-mediated signaling. The compound's structure indicates it may interact with metabolic enzymes or cellular transporters, but the exact molecular target and mechanism of action have not been publicly disclosed by Valenta Pharm.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. (PHASE2)
- Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral Infections (PHASE4)
- Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections (PHASE3)
- Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19 (PHASE3)
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o. (PHASE3)
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o. (PHASE3)
- Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imidazolyl ethanamide pentandioic acid CI brief — competitive landscape report
- Imidazolyl ethanamide pentandioic acid updates RSS · CI watch RSS
- Valenta Pharm JSC portfolio CI